MAPT and Alzheimer disease: Mounting evidence supports a toxic gain-of-function role of APOE4 in AD pathogenesis, with studies in preclinical models consistently demonstrating that reducing APOE4 levels alleviates multiple pathological features, including amyloid and tau pathology, neurodegeneration, and neuroinflammation.